Although the specific targeting of FGF19 by 1A6 has been shown to effectively inhibit tumor growth and highlight the therapeutic potential of FGF19 for treating CRC and HCC, there remains the possibility of non-specific binding to other proteins, resulting in unintended signaling or immune reactions. This evidence concerns the gene FGF19 and hepatocellular carcinoma.